Organization (Hospital)
NHS Tayside
ClinicalTrials.gov lists NHS Tayside as lead sponsor of 29 trials, counting the companies grouped under it. NHS Tayside itself has 1 active development program and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers NHS Tayside and 1 company grouped under it: 29 lead-sponsored trials (28 its own, 1 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Ninewells Hospital | 1 | 1 |
Disease areas (82)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 7 |
| Diabetes Mellitus, Type 2 | 7 |
| Hepatitis C | 5 |
| Breast Neoplasms | 4 |
| Pulmonary Disease, Chronic Obstructive | 4 |
Showing 5 of 82 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 10 |
| 2017 | 4 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: none of the 28 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Standard Care | Pulmonary Disease, Chronic Obstructive | Not reported | 1 |
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| METFORMIN | 3 |
| Omeprazole | 1 |
| Ropivacaine | 1 |
| PIOGLITAZONE | 1 |
| local anaesthetic injection | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 56% hit target (n=9) | 44% on time (n=9) |
Journals published in (71)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 8 |
| Trials | 6 |
| Heart (British Cardiac Society) | 5 |
| Journal of the American College of Cardiology | 4 |
| The New England journal of medicine | 4 |
Showing 5 of 71 journals.
Organization relationships (52)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| NHS Greater Glasgow and Clyde | Co sponsors trial with | 4 |
| NHS Lanarkshire | Co sponsors trial with | 3 |
| University of Dundee | Co sponsors trial with | 3 |
| NHS Lothian | Co sponsors trial with | 3 |
| NHS Grampian | Co sponsors trial with | 2 |
Showing 5 of 52 relationships.
Latest dated events (77)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 77 events.
Biomarker capability evidence (77)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ARID3B | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial inclusion criteria |
| GLP1R | Trial collaborator | Named in trial inclusion criteria |
| KLK3 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 77 evidence rows.
Biomarkers this organization publishes on (223)
Shown in this order: most publications first.
Showing 5 of 223 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.